Previous 10 | Next 10 |
Full year clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced prelimi...
Guardant Health ( NASDAQ: GH ) earlier briefly ticked higher, now down 2.1%, amid speculation it could be a possible takeover target for Agilent Technologies ( NYSE: A ). Guardant Health ( GH ) shares ticked higher amid a Gordon Haskett note that speculated the co...
Summary We dive under the hood of one of the most controversial exchange-traded funds, analyzing their moves based on recently disclosed 13F filing data. Cathie Wood is a uniquely divisive figure in the world of finance made famous by her "disruptive innovation" investment philosophy, w...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference. Guardant Health’s management is scheduled to present and participate in a Q&A session on M...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test Susan G. Komen Advocates in Science will provide patient perspective to inform design of research studies and strategies for ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avaya (NYSE: AVYA ) stock is falling hard on Friday following reports that the company is closing in on a bankruptcy filing . According to these recent reports, insiders at Avaya have concerns about the company’...
- The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90% - Results pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening - The company will host a webcast and conference call to discuss th...
Innovation drives progress, and in the healthcare sector, that often means saving lives by finding new ways to diagnose or treat potentially deadly illnesses. Those companies at the forefront of innovation can help improve the lives of thousands of people while providing outsized returns to inves...
Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, ann...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...